Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Pharmaceutical Business Review
Return to: PBR Home
Search Refinements

News

View news from other Pharmaceutical sectors:
136-150 of 49615 results
Indivior’s opioid-treatment study of RBP-6000 meets primary and secondary endpoints
By PBR Staff Writer
A phase 3 clinical trial of Indivior’s RBP-6000 buprenorphine monthly depot, a new drug for the treatment of opioid use disorder, has met both primary and secondary endpoints versus placebo.
Contract Research & Services > Clinical Trials > News
Mayne Pharma acquires rights to portfolio of dermatology Foam products
Mayne Pharma is pleased to announce it has acquired a portfolio of on-market dermatology Foam Assets from GSK for $50.1m.
News
Wolters Kluwer announces Sentri7 capabilities for Direct CDA Automation of NHSN reporting
The Health division of Wolters Kluwer, a global provider of information and point of care solutions for the healthcare industry, announced today the release of updates to its Sentri7 electronic surveillance solution.
News
Tioma Therapeutics raises $86m to further develop antibody portfolio
By PBR Staff Writer
Tioma Therapeutics, a venture-stage biopharmaceutical firm focused on the development of anti-CD47 antibodies to treat solid and hematologic cancers, has raised $86m in Series A venture financing.
Drug Research > Drug Discovery & Development > News
Eleven Biotherapeutics completes exclusive licensing deal for IL-6 antagonist antibody technology
Eleven Biotherapeutics, a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, announced the effectiveness of the exclusive licensing deal with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. (Roche).
Automation > IT & Software > News
Avacta opens two new facilities in Cambridge and Wetherby
Avacta Group, the developer of Affimer biotherapeutics and research reagents, has opened two new facilities, in Cambridge and Wetherby, Yorkshire.
Production & Manufacturing > Manufacturing > News
Xycrobe signs research deal with Johnson & Johnson Consumer
Xycrobe Therapeutics has entered into a research agreement with Johnson & Johnson Consumer.
Contract Research & Services > Contract Research > News
ViiV Healthcare starts testing new HIV treatment
By PBR Staff Writer
ViiV Healthcare, a joint venture of GlaxoSmithKline and Pfizer, has started testing a new two-drug treatment for HIV treatment.
Contract Research & Services > Clinical Trials > News
Tissue Regeneration engineered mesenchymal stromal cells advance monoclonal antibody therapy
Tissue Regeneration Therapeutics announced that a team of Canadian researchers has for the first time shown that TRT's engineered mesenchymal stromal cell product (eTXP) can be used to deliver therapeutically useful monoclonal antibodies (mAbs) more effectively than administration of the mAbs themselves.
Drug Research > Drug Delivery > News
Neurotrope submits amended protocol to FDA for phase 2 clinical trial of bryostatin-1
Neurotrope's subsidiary Neurotrope BioScience has submitted to the Food and Drug Administration (FDA) an amended protocol for its Phase 2 clinical trial of lead candidate bryostatin-1 for the treatment of advanced Alzheimer’s disease.
Production & Manufacturing > Process & Production > News
Vertex stops phase 3 study for VX-661 in combination with ivacaftor to treat cystic fibrosis
By PBR Staff Writer
Vertex Pharmaceuticals has stopped one of its phase 3 clinical trials looking at the combination of VX-661 with ivacaftor to treat cystic fibrosis (CF).
Contract Research & Services > Clinical Trials > News
NeuroVive Pharmaceutical completes 10% acquisition of Isomerase Therapeutics
NeuroVive Pharmaceutical has completed the second step in the previously announced partial acquisition of the British drug discovery and development company Isomerase Therapeutics.
Drug Research > Drug Discovery & Development > News
Aurinia’s Voclosporin meets primary endpoint in phase 2b lupus nephritis trial
By PBR Staff Writer
A phase 2b clinical trial assessing Aurinia Pharmaceuticals’ Voclosporin met its primary efficacy endpoint in patients with active lupus nephritis (LN), an inflammation of the kidney caused by the autoimmune disorder systemic lupus erythematosus (SLE).
Contract Research & Services > Clinical Trials > News
Acacia Pharma unveils positive results from phase 3 trial of BAREMSIS to treat PONV
Acacia Pharma has unveiled positive results from a pivotal Phase 3 study investigating BAREMSIS (amisulpride injection, formerly APD421) for the treatment of established post-operative nausea & vomiting (PONV).
Contract Research & Services > Clinical Trials > News
Arrowhead Pharmaceuticals closes $45m private offering
Arrowhead Pharmaceuticals (ARWR) has closed a previously announced private offering with a select group of investors that include Orbimed, RA Capital Management, Perceptive Advisors, RTW Investments and other institutional investors.
Drug Research > Drug Discovery & Development > News
136-150 of 49615 results